HK Innoen 'K-CAB' Begins Export to Mongolia Following China
[Asia Economy Reporter Lee Chun-hee] HK Innoen recently announced on the 26th that it has completed preparations to begin full-scale sales in Mongolia by shipping the new drug for gastroesophageal reflux disease (GERD), K-CAB tablets (active ingredient: Tegoprazan), to Mongolia. This shipment marks the second actual overseas launch following China among the 34 countries where overseas expansion has been confirmed. Local distribution will be handled by Monos Pharma, the top pharmaceutical company in Mongolia with a chain of over 200 pharmacies.
The company explained, "K-CAB is the first potassium-competitive acid blocker (P-CAB) new drug to be launched in the Mongolian market," adding, "It is expected to lead a generational shift in GERD treatment from the existing proton pump inhibitor (PPI) class to the P-CAB class." Previously, PPI drugs were mainly used for GERD treatment. However, PPI formulations require administration 30 minutes before meals and have the inconvenience of acid secretion occurring at night due to stimulation of acid secretion. Side effects such as osteoporosis and stroke have also been controversial. In contrast, P-CAB formulations can be taken regardless of meal times and have improved nighttime heartburn.
HK Innoen signed the export contract for K-CAB to Mongolia in August 2020 and obtained local approval last October. The shipped K-CAB is scheduled to be launched in Mongolia next month. The local distribution partner, Monos Pharma, is the top pharmaceutical company in Mongolia in terms of drug sales. Ahead of K-CAB’s launch in Mongolia, Monos Pharma participated in the ‘Mongolian Digestive Disease Week’ symposium hosted by the Mongolian Gastroenterology Society in June, where it presented the main features, indications, and effects of K-CAB to Mongolian medical professionals.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- Fed Turns Hawkish in a Month, Hints at Possibility of "Additional Policy Firming"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
An HK Innoen official stated, “In the Mongolian market, digestive diseases have been the leading cause of incidence over the past 10 years until 2020, and due to a culture that favors meat and alcohol, more than half of the total population is known to be overweight or obese,” adding, “Since obesity is considered one of the causes of GERD, the market for GERD treatments in Mongolia is expected to grow further in the future.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
